Toralizumab

{{Short description|Monoclonal antibody}}

{{About|a drug||IDEC (disambiguation){{!}}IDEC}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 470611840

| image =

| type = mab

| mab_type = mab

| source = zu/o

| target = CD40 ligand

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 252662-47-8

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = KX44A9HM0B

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D06193

| chemical_formula =

}}

Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenström's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).[http://www.ama-assn.org/ama1/pub/upload/mm/365/toralizumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab], American Medical Association.

In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.{{cite book| vauthors = Luebke RW, House RV, Kimber I |title=Immunotoxicology and immunopharmacology|publisher=CRC Press, Taylor & Francis Group |location=Boca Raton, Florida |year=2007 |edition = 3rd |series=Target Organ Toxicology Series|page=131|isbn=978-0-8493-3790-1 |url= https://books.google.com/books?id=L7G38ea2wnAC&q=Toralizumab&pg=PA131}}

The drug was developed by IDEC Pharmaceuticals Corporation.